屈螺酮与高钾血症的相关性:一项比较安全性研究。

Steven T Bird, Salvatore R Pepe, Mahyar Etminan, Xinyue Liu, James M Brophy, Joseph Ac Delaney
{"title":"屈螺酮与高钾血症的相关性:一项比较安全性研究。","authors":"Steven T Bird,&nbsp;Salvatore R Pepe,&nbsp;Mahyar Etminan,&nbsp;Xinyue Liu,&nbsp;James M Brophy,&nbsp;Joseph Ac Delaney","doi":"10.1186/1472-6904-11-23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drospirenone/ethinyl-estradiol is an oral contraceptive (OC) that possesses unique antimineralocorticoid activity. It is conjectured that drospirenone, taken alone or concomitantly with spironolactone, may be associated with an increased risk of hyperkalemia.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted evaluating women between 18-46 years of age in the Lifelink™ Health Plan Claims Database. The study was restricted to new users of OCs between 1997-2009. Cox proportional hazards models were used to estimate the time to first occurrence of hyperkalemia diagnosis. The main analysis compared OCs containing drospirenone with OCs containing levonorgestrel, a second generation OC not known to impact potassium homeostasis. Logistic regression evaluated concomitant prescribing of drospirenone and spironolactone</p><p><strong>Results: </strong>The cohort included 1,148,183 women, averaging 28.8 years of age and 280 days of OC therapy. 2325 cases of hyperkalemia were identified. The adjusted hazard ratio (HR) for hyperkalemia with drospirenone compared to levonorgestrel was 1.10 (95%CI 0.95-1.26). There was an increased risk of hyperkalemia with norethindrone HR 1.15 (95%CI: 1.00-1.33) and norgestimate HR 1.27 (95%CI: 1.11-1.46). Other OCs were unassociated with hyperkalemia. The odds of receiving spironolactone while taking drospirenone were 2.66 (95%CI 2.53-2.80) times higher than the odds of receiving spironolactone and levonorgestrel. Only 6.5% of patients taking drospirenone and spironolactone had a serum potassium assay within 180 days of starting concomitant therapy.</p><p><strong>Conclusions: </strong>A clinically significant signal for hyperkalemia with drospirenone was not demonstrated in the current study. Despite the bolded warning for hyperkalemia with joint drospirenone and spironolactone administration, physicians are actually using them together preferentially, and are not following the recommended potassium monitoring requirements in the package insert.</p>","PeriodicalId":9196,"journal":{"name":"BMC Clinical Pharmacology","volume":"11 ","pages":"23"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1472-6904-11-23","citationCount":"31","resultStr":"{\"title\":\"The association between drospirenone and hyperkalemia: a comparative-safety study.\",\"authors\":\"Steven T Bird,&nbsp;Salvatore R Pepe,&nbsp;Mahyar Etminan,&nbsp;Xinyue Liu,&nbsp;James M Brophy,&nbsp;Joseph Ac Delaney\",\"doi\":\"10.1186/1472-6904-11-23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Drospirenone/ethinyl-estradiol is an oral contraceptive (OC) that possesses unique antimineralocorticoid activity. It is conjectured that drospirenone, taken alone or concomitantly with spironolactone, may be associated with an increased risk of hyperkalemia.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted evaluating women between 18-46 years of age in the Lifelink™ Health Plan Claims Database. The study was restricted to new users of OCs between 1997-2009. Cox proportional hazards models were used to estimate the time to first occurrence of hyperkalemia diagnosis. The main analysis compared OCs containing drospirenone with OCs containing levonorgestrel, a second generation OC not known to impact potassium homeostasis. Logistic regression evaluated concomitant prescribing of drospirenone and spironolactone</p><p><strong>Results: </strong>The cohort included 1,148,183 women, averaging 28.8 years of age and 280 days of OC therapy. 2325 cases of hyperkalemia were identified. The adjusted hazard ratio (HR) for hyperkalemia with drospirenone compared to levonorgestrel was 1.10 (95%CI 0.95-1.26). There was an increased risk of hyperkalemia with norethindrone HR 1.15 (95%CI: 1.00-1.33) and norgestimate HR 1.27 (95%CI: 1.11-1.46). Other OCs were unassociated with hyperkalemia. The odds of receiving spironolactone while taking drospirenone were 2.66 (95%CI 2.53-2.80) times higher than the odds of receiving spironolactone and levonorgestrel. Only 6.5% of patients taking drospirenone and spironolactone had a serum potassium assay within 180 days of starting concomitant therapy.</p><p><strong>Conclusions: </strong>A clinically significant signal for hyperkalemia with drospirenone was not demonstrated in the current study. Despite the bolded warning for hyperkalemia with joint drospirenone and spironolactone administration, physicians are actually using them together preferentially, and are not following the recommended potassium monitoring requirements in the package insert.</p>\",\"PeriodicalId\":9196,\"journal\":{\"name\":\"BMC Clinical Pharmacology\",\"volume\":\"11 \",\"pages\":\"23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/1472-6904-11-23\",\"citationCount\":\"31\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Clinical Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/1472-6904-11-23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1472-6904-11-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 31

摘要

背景:屈螺酮/乙炔雌二醇是一种口服避孕药,具有独特的抗糖皮质激素活性。据推测,单独服用或与螺内酯一起服用的屈螺酮可能与高钾血症风险增加有关。方法:对Lifelink中18-46岁的女性进行回顾性队列研究™ 健康计划索赔数据库。这项研究仅限于1997-2009年间OCs的新用户。Cox比例风险模型用于估计高钾血症诊断首次发生的时间。主要分析将含有屈螺酮的OC与含有左炔诺孕酮的OC进行了比较,左炔诺孕是一种不知道会影响钾稳态的第二代OC。Logistic回归评估了屈螺酮和螺内酯的联合用药结果:该队列包括1148183名女性,平均年龄28.8岁,接受OC治疗280天。发现2325例高钾血症。与左炔诺孕酮相比,屈螺酮治疗高钾血症的调整后危险比(HR)为1.10(95%CI 0.95-1.26)。炔诺酮HR 1.15(95%CI:1.00-1.33)和诺孕酯HR 1.27(95%CI:1.11-1.46)治疗高钾症的风险增加。其他强迫症与高钾血症无关。服用屈螺酮同时服用螺内酯的几率是服用螺内酯和左炔诺孕酮几率的2.66倍(95%CI 2.53-2.80)。在服用屈螺酮和螺内酯的患者中,只有6.5%的患者在开始联合治疗的180天内进行了血清钾测定。结论:在目前的研究中,drospirone对高钾血症没有临床意义的信号。尽管联合使用屈螺酮和螺内酯对高钾血症发出了大胆的警告,但医生实际上优先将它们一起使用,并且没有遵循说明书中建议的钾监测要求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The association between drospirenone and hyperkalemia: a comparative-safety study.

Background: Drospirenone/ethinyl-estradiol is an oral contraceptive (OC) that possesses unique antimineralocorticoid activity. It is conjectured that drospirenone, taken alone or concomitantly with spironolactone, may be associated with an increased risk of hyperkalemia.

Methods: A retrospective cohort study was conducted evaluating women between 18-46 years of age in the Lifelink™ Health Plan Claims Database. The study was restricted to new users of OCs between 1997-2009. Cox proportional hazards models were used to estimate the time to first occurrence of hyperkalemia diagnosis. The main analysis compared OCs containing drospirenone with OCs containing levonorgestrel, a second generation OC not known to impact potassium homeostasis. Logistic regression evaluated concomitant prescribing of drospirenone and spironolactone

Results: The cohort included 1,148,183 women, averaging 28.8 years of age and 280 days of OC therapy. 2325 cases of hyperkalemia were identified. The adjusted hazard ratio (HR) for hyperkalemia with drospirenone compared to levonorgestrel was 1.10 (95%CI 0.95-1.26). There was an increased risk of hyperkalemia with norethindrone HR 1.15 (95%CI: 1.00-1.33) and norgestimate HR 1.27 (95%CI: 1.11-1.46). Other OCs were unassociated with hyperkalemia. The odds of receiving spironolactone while taking drospirenone were 2.66 (95%CI 2.53-2.80) times higher than the odds of receiving spironolactone and levonorgestrel. Only 6.5% of patients taking drospirenone and spironolactone had a serum potassium assay within 180 days of starting concomitant therapy.

Conclusions: A clinically significant signal for hyperkalemia with drospirenone was not demonstrated in the current study. Despite the bolded warning for hyperkalemia with joint drospirenone and spironolactone administration, physicians are actually using them together preferentially, and are not following the recommended potassium monitoring requirements in the package insert.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信